[go: up one dir, main page]

ATE363280T1 - Verwendung von pioglitazone zur verbesserung der ketose und der azidose - Google Patents

Verwendung von pioglitazone zur verbesserung der ketose und der azidose

Info

Publication number
ATE363280T1
ATE363280T1 AT00915509T AT00915509T ATE363280T1 AT E363280 T1 ATE363280 T1 AT E363280T1 AT 00915509 T AT00915509 T AT 00915509T AT 00915509 T AT00915509 T AT 00915509T AT E363280 T1 ATE363280 T1 AT E363280T1
Authority
AT
Austria
Prior art keywords
ketosis
acidose
pioglitazone
improve
agent
Prior art date
Application number
AT00915509T
Other languages
English (en)
Inventor
Hiroyuki Odaka
Masami Suzuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE363280T1 publication Critical patent/ATE363280T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT00915509T 1999-04-14 2000-04-13 Verwendung von pioglitazone zur verbesserung der ketose und der azidose ATE363280T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10711999 1999-04-14

Publications (1)

Publication Number Publication Date
ATE363280T1 true ATE363280T1 (de) 2007-06-15

Family

ID=14450976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00915509T ATE363280T1 (de) 1999-04-14 2000-04-13 Verwendung von pioglitazone zur verbesserung der ketose und der azidose

Country Status (14)

Country Link
US (2) US6677363B1 (de)
EP (1) EP1169037B1 (de)
KR (1) KR100697582B1 (de)
CN (1) CN1222289C (de)
AT (1) ATE363280T1 (de)
AU (1) AU3677900A (de)
CA (1) CA2369694C (de)
DE (1) DE60035032T2 (de)
ES (1) ES2283291T3 (de)
HU (1) HUP0201653A3 (de)
NO (1) NO20014935L (de)
PL (1) PL352021A1 (de)
TW (1) TWI249401B (de)
WO (1) WO2000061127A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
CN1423566A (zh) * 1999-11-10 2003-06-11 武田药品工业株式会社 体重增加抑制剂
WO2001058491A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Drug comprising combination
GB0027783D0 (en) * 2000-11-14 2000-12-27 S P A Novel use
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ATE480236T1 (de) * 2001-04-25 2010-09-15 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
EP1688148A1 (de) * 2002-12-03 2006-08-09 Novo Nordisk A/S Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen
EP1569682A2 (de) * 2002-12-03 2005-09-07 Novo Nordisk A/S Kombinationsbehandlung mit exendin-4 undthiazolidindionen
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MY180761A (en) * 2013-03-19 2020-12-08 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN109562105A (zh) * 2016-08-17 2019-04-02 企业支持有限责任公司 预防或治疗听力损失的方法
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2019154893A1 (en) * 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
KR102180524B1 (ko) * 2018-11-16 2020-11-18 순천대학교 산학협력단 반추동물의 산독증 예방용 완충제 조성물
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU3192195A (en) * 1994-08-10 1996-03-07 Takeda Chemical Industries Ltd. Thiazolidinedione derivatives, their production and use
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
MY123337A (en) * 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
WO2000000195A1 (en) * 1998-06-30 2000-01-06 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes

Also Published As

Publication number Publication date
CN1347319A (zh) 2002-05-01
KR100697582B1 (ko) 2007-03-22
HUP0201653A2 (en) 2002-09-28
US20040106649A1 (en) 2004-06-03
EP1169037A2 (de) 2002-01-09
EP1169037B1 (de) 2007-05-30
ES2283291T3 (es) 2007-11-01
DE60035032D1 (de) 2007-07-12
HUP0201653A3 (en) 2004-12-28
KR20010108497A (ko) 2001-12-07
WO2000061127A2 (en) 2000-10-19
AU3677900A (en) 2000-11-14
US6677363B1 (en) 2004-01-13
US7595333B2 (en) 2009-09-29
NO20014935D0 (no) 2001-10-10
NO20014935L (no) 2001-12-12
TWI249401B (en) 2006-02-21
CN1222289C (zh) 2005-10-12
CA2369694A1 (en) 2000-10-19
CA2369694C (en) 2011-01-04
WO2000061127A3 (en) 2001-09-07
PL352021A1 (en) 2003-07-14
DE60035032T2 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
ATE363280T1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DK1112275T3 (da) Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
IS7638A (is) Asabísýkló-oktan- og nónanafleiður með DDP-IV tálmunarvirkni
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
MY142777A (en) Substituted indole-o-glucosides
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
UA86042C2 (en) Substituted indazole-o-glucosides
PT1147103E (pt) Fenantridina-n-oxidos com actividade inibitoria de pde-iv
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
DK1147088T3 (da) 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
PT1147087E (pt) Feantridina-n-oxidos com actividade de inibicao de pde-iv
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
DE60033809D1 (de) Inhibitoren von metalloproteinasen
EP1144690A4 (de) Antisense modulation der expression des zellulären hemmstoffs der apoptose-2
DE69735479D1 (de) Metalloproteinase inhibitoren
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
DK1244643T3 (da) Tryptaseinhibitorer
DE60011300D1 (de) Inhibitoren der tryptase
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
ATE309701T1 (de) Verwendung von riboflavin und flavinderivaten als inhibitoren von chitinasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169037

Country of ref document: EP